Following recent constructive FDA feedback, Seres anticipates finalizing SER-155 Phase 2 study protocol for the prevention of bloodstream infections in adults undergoing allogeneic hematopoietic stem ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback